Trials / Recruiting
RecruitingNCT06439589
Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial, which aims to observe and evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of HRS2398 combined with Adebrelimab injection in patients with advanced solid tumors, determine the RP2D, and preliminarily evaluate the efficacy of HRS2398 combined with Adebrelimab in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS2398 | HRS2398: Tablets, 40mg/tablet, oral |
| DRUG | Adebrelimab | Adebrelimab (SHR-1316): injection, 600mg(12mL), intravenous infusion |
Timeline
- Start date
- 2024-06-12
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-06-03
- Last updated
- 2024-07-05
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06439589. Inclusion in this directory is not an endorsement.